These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34718447)

  • 21. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evaluation of a home-based program for hands in patients with systemic sclerosis.
    Landim SF; Bertolo MB; Marcatto de Abreu MF; Del Rio AP; Mazon CC; Marques-Neto JF; Poole JL; de Paiva Magalhães E
    J Hand Ther; 2019; 32(3):313-321. PubMed ID: 29198478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treprostinil Hydrogel Iontophoresis in Systemic Sclerosis-Related Digital Skin Ulcers: A Safety Study.
    Guigui A; Mazet R; Blaise S; Cracowski C; Beau-Guillaumot M; Kotzki S; Roustit M; Cracowski JL
    J Clin Pharmacol; 2020 Jun; 60(6):758-767. PubMed ID: 32080862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. X-ray diffraction analysis of spontaneously draining calcinosis in scleroderma patients.
    Hsu VM; Emge T; Schlesinger N
    Scand J Rheumatol; 2017 Mar; 46(2):118-121. PubMed ID: 27682520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
    Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
    Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
    Becker MO; Dobrota R; Garaiman A; Debelak R; Fligelstone K; Tyrrell Kennedy A; Roennow A; Allanore Y; Carreira PE; Czirják L; Denton CP; Hesselstrand R; Sandqvist G; Kowal-Bielecka O; Bruni C; Matucci-Cerinic M; Mihai C; Gheorghiu AM; Mueller-Ladner U; Sexton J; Kvien TK; Heiberg T; Distler O
    Ann Rheum Dis; 2022 Apr; 81(4):507-515. PubMed ID: 34824049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis.
    Shetty S; Moore TL; Jackson S; Brettle D; Herrick AL
    Rheumatology (Oxford); 2005 Apr; 44(4):536-8. PubMed ID: 15644389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study.
    Avouac J; Mogavero G; Guerini H; Drapé JL; Mathieu A; Kahan A; Allanore Y
    Ann Rheum Dis; 2011 Apr; 70(4):630-3. PubMed ID: 21131648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of Turkish version of the Scleroderma Health Assessment Questionnaire.
    Temiz Karadag D; Karakas F; Tekeoglu S; Yazici A; Isik OO; Cefle A
    Clin Rheumatol; 2019 Jul; 38(7):1917-1923. PubMed ID: 30840212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical Debulking for Symptomatic Management of Calcinosis Cutis of the Hand and Upper Extremity in Systemic Sclerosis.
    Klifto KM; Cho BH; Lifchez SD
    J Hand Surg Am; 2021 Oct; 46(10):928.e1-928.e9. PubMed ID: 33795151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.
    Khanna D; Furst DE; Wong WK; Tsevat J; Clements PJ; Park GS; Postlethwaite AE; Ahmed M; Ginsburg S; Hays RD;
    Qual Life Res; 2007 Aug; 16(6):1083-92. PubMed ID: 17404896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis.
    Hsu V; Bramwit M; Schlesinger N
    Clin Rheumatol; 2015 Sep; 34(9):1557-61. PubMed ID: 26134593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study.
    Roustit M; Gaillard-Bigot F; Blaise S; Stanke-Labesque F; Cracowski C; Seinturier C; Jourdil JF; Imbert B; Carpentier PH; Cracowski JL
    Clin Pharmacol Ther; 2014 Apr; 95(4):439-45. PubMed ID: 24458011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.